CTRI/2024/08/072343尚未招募3 期
Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - MMRd-GREEN [RAINBO] - RAINBO MMRd Green
eiden University Medical Center0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Histologically confirmed diagnosis of EC of the following histologic subtypes: endometrioid
- •endometrial carcinoma, serous endometrial carcinoma, uterine clear cell carcinoma,
- •dedifferentiated and undifferentiated endometrial carcinoma, uterine carcinosarcoma, and
- •mixed endometrial carcinomas of the aforementioned histotypes.
- •Full molecular classification performed following the diagnostic algorithm described in WHO
- •2020 (5th Edition, IARC, Lyon, 2020, adapted from Vermij et al. 2020)
- •TLH-BSO or TAH-BSO with or without lymphadenectomy or sentinel node biopsy, without
- •macroscopic residual disease after surgery
- •No distant metastases as determined by pre-surgical or post-surgical imaging (CT/MRI scan
- •of chest, abdomen and pelvis or PET-CT scan)
排除标准
- •History of another primary malignancy, except for non-melanoma skin cancer, in the past 5
- •Prior pelvic irradiation
研究者
相似试验
招募中
1 期
Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials – p53abn - REDRandomized phase III trial testing maintenance olaparib versus observation after adjuvant chemoradiation for p53abn endometrial cancerPatients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastasesCTIS2023-503886-44-00Institut Gustave Roussy150
已完成
2 期
Adjuvant Chemotherapy for Endometrial cancer Trial: A randomised phase II study of TEC, TAC and ddTC for endometrial carcinomaEndometrial carcinoma with risk factors of recurrence.JPRN-UMIN000008368Gynecologic Oncology Group of Osaka (GOGO)90
招募中
3 期
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, MMRd-GREEN trialNL-OMON54178eids Universitair Medisch Centrum150
招募中
1 期
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials (MMRd-GREEN)Patients with a histological diagnosis of MMRd HREC, with mismatch- repair deficient high risk endometrial cancer (MMRdHRECno POLEmutall histology including carcinosarcoma), Stage IB/II with substantial LVSI or stage IIIA-C. Patients are treated with curative intent, after surgery (hysterectomy and bilateralsalpingo-oophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases.CTIS2023-503267-42-00eiden University Medical Center304
进行中（未招募）
1 期
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, The MMRD-GREEN trialEndometrial CancerEUCTR2021-000518-40-NLeiden University Medical Center316